Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Signs Aptamer Deal With Archemix
by Lisa M. Jarvis
January 5, 2009
| A version of this story appeared in
Volume 87, Issue 1
GlaxoSmithKline has linked with Archemix to develop aptamer therapeutics, or synthesized oligonucleotides, against seven targets related to inflammatory diseases. GSK is taking a $6.5 million stake in Archemix, which recently announced a merger with fellow Boston-area biotech firm NitroMed. Archemix also gains an additional $21 million upfront and could receive up to $200 million in milestone payments for each of the seven aptamer targets covered in the deal. The biotech firm will be tasked with developing the aptamer therapeutics through clinical proof-of-mechanism.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter